GB001 in Adult Subjects With Moderate to Severe Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
GB001
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring GB001, eosinophilic asthma, moderate asthma, severe asthma
Eligibility Criteria
Inclusion Criteria
- A diagnosis of asthma by a physician at least 12 months before Screening Visit.
- Treated with medium or high dose inhaled corticosteroid (ICS) plus additional controller for at least 12 months prior to Screening Visit. Subjects must maintain a stable ICS dose regimen during the 4 weeks prior to the Screening Visit.
- Forced Expiratory Volume in 1 second (FEV1) of ≤ 85% of predicted normal
- Demonstrated reversibility of at least 12% in FEV1
- Evidence of uncontrolled asthma
- Eosinophilic asthma
- No changes in ICS dose and compliant with standard of care asthma therapy during run-in period.
Exclusion Criteria
- Current smokers (any substance)
- Serious co-morbidities
- Fridericia's correction QT factor (QTcF) ≥450 msec (male) or ≥470 msec (female)
- Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit
- Regular use of systemic corticosteroids or immunosuppressive treatments or monoclonal antibodies for asthma
- Pregnant or breastfeeding
Other protocol-defined inclusion/exclusion criteria may apply.
Sites / Locations
- Clinical Research Center of Albama, LLC
- Banner University of Arizona Medical Center
- California Allergy and Asthma Medical Group
- Southern California Institute for Respiratory Diseases, Inc.
- North Bay Clinical Trials, Inc
- Allergy, Asthma & Sinus Consultants, Inc
- Integrated Research of Inland, Inc.
- Allergy & Asthma Medical Group and Research Center, A P.C.
- Allergy and Asthma Associates of Santa Clara Valley Research Center
- Bensch Clinical Research LLC
- Pulmonary Associates
- Yale New Haven Hospital
- Central Florida Pulmonary Group, PA
- Central Florida Pulmonary Group, PA
- Emerald Coast Research Associates
- Allergy and Asthma Diagnostic Treatment Center
- Clinical Research Trials of Florida, Inc.
- The Emory Clinic
- Atlanta Allergy & Asthma Clinic, PA,
- Atlanta Allergy & Asthma Clinic, PA
- Treasure Valley Medical Research
- Rush University Medical Center
- Allergy & Asthma Specialists, PSC
- John Hopkins Asthma and Allergy Center
- Brigham and Women's Hospital
- University of Michigan Medicine
- Clinical Research Institute, Inc.
- Washington University School of Medicine
- Atlantic Research Center, LLC
- American Health Research
- Clinical Research of Charlotte
- Wake Forest Baptist Health
- Bernstein Clinical Research Center, LLC
- Cleveland Clinic
- Oklahoma Institute of Allergy & Asthma Clinical Research, LLC
- Crisor, LLC
- Allergy and Clinical Immunology Associates
- Berks Schuylkill Respiratory Specialists, Ltd.
- AAPRI Clinical Research Institute
- Clinical Research of Rock Hill
- Corsicana Medical Research, LLC
- Western Sky Medical Research
- Baylor College of Medicine
- Allergy and Asthma Research Center, PA
- Pulmonary Research of Abingdon, LLC
- MultiCare Institute for Research & Innovation
- University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research
- Ordination Dr. Robert Voves
- SALK University Hospital Salzburg, State Hospital Salzburg
- Medical University of Vienna, Department of Internal Medicine II, Clinical Division of Pulmonolog
- UCL Saint-Luc - Pneumology Department
- Pneumocare sprl
- UZ Gent - Department of Respiratory Medicine
- CHU de Charleroi - Site André Vésale
- Inspiration Research Limited
- CHUM - Departement de pneumologie
- Allergiste & Immunologue - Clinic/Outpatient Facility
- Centre integre universitaire de sante et de services sociaux du Nord-de-I'lle-de-Montreal - Hopital du Sacre-Coeur de Montreal
- Dr. Jamie Del Carpio's Clinic
- Inspirational Research Limited
- C. I. C Mauricie Inc.
- The Lung Centre, Vancouver General Hospital
- St. Anne's University Hospital Brno, Institute of Clinical Immunology and Allergology
- University Hospital Hradec Kralove, Institute of Clinical Immunology and Allergollogy
- MediTrial s.r.o.
- PNEUMO-KV s.r.o.
- Pulmonary Outpatient Clinic - Dr. Otakar Hokynar
- University Hospital Olomouc, Department of Allergology and Clinical Immunology
- Medicon a.s.
- Pulmonary Outpatient Clinic Rokycany s.r.o.
- Outpatient Allergology and Neurology Clinic Kasmed Ltd.
- La Croix Rousse Hospital
- Nord G&R Laennec Hospital
- Centre Hospitalier Annecy Genevois
- NOUVEL HOPITAL CIVIL - New Civil Hospital
- Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin V
- RCMS Dr. Linhoff
- Pneumologisches Studienzentrum Margrafenstrasse
- Institut fuer Allergie - und Asthmaforschung
- Pneumologische Praxis am Schloss
- IKF Pneumologie GmbH & Co. KG
- Pneumologicum im Suedstadtforum
- Schmid
- BAG Prof. Hoheisel/Dr. A. Bonitz
- Pneumologische Praxis PD Dr. med.
- KLB Gesundheitsforschung Luebeck GmbH
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Hospital
- Centrum Medycyny Oddechowej Mroz sp. j.
- Malopolskie Centrum Alergologii
- Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ)
- Ostrowieckie Centrum Medyczne
- SPZOZ Proszowice
- Gabinet Lekarski Zenon Bukowczan
- ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy Marek Jutel
- Centrum Medyczne Melita Medical
- NZOZ Lekarze Specjalisci
- SPZOZ Uniwersytecki Szpital Kliniczny nr 1
- Hospital Clinico Universitario de Santiago de Compostela
- Hospital Universitario de Bellvitge
- Instituto de Ciencias Medicas
- Hospital Clinic de Barcelona
- Hospital Universitari Vall d'Hebron
- Hospital Universitario Doctor Peset
- Public Institution: Dnipro Clinical Association of Urgent Medical Care under Dnipro City Council
- Public Institution "City Clinical Hospital #4" under Dnipro City Council
- Ivano-Frankivsk Central City Clinical Hospital
- Public Non-Profit Enterprise: City Clinical Hospital #13 under Kharkiv City Council
- State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"
- State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"
- Public Institution: City Clinical Hospital #6
- Public Non-Profit Enterprise City Hospital #1 under Zaporizhia City Council
- Public Enterprise "Hospital #1" under Zhytomyr City Council
- Birmingham Heartlands Hospital
- Bradford Royal Infirmary
- Glasgow Clinical Research Facility, Glasgow Royal Infirmary
- Royal Liverpool University Hospital
- University Hospital Southampton
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Placebo Comparator
Experimental
Experimental
Experimental
Arm Label
Placebo
GB001 20 mg
GB001 40 mg
GB001 60 mg
Arm Description
Placebo once per day (QD) for 24 weeks
GB001 20 mg QD for 24 weeks
GB001 40 mg QD for 24 weeks
GB001 60 mg QD for 24 weeks
Outcomes
Primary Outcome Measures
Proportion of Participants Who Experience Worsening of Asthma by Week 24
Proportion of participants who experience worsening of asthma by Week 24 as defined by at least 1 of the following:
On 2 consecutive days, morning (AM) peak expiratory flow (PEF) ≤ 75% of mean AM PEF measured over the last 7 days of the Run-in
Forced expiratory volume in 1 second (FEV1) < 80% of baseline
Increase in rescue medication use of ≥ 6 puffs/day on 2 consecutive days compared to mean use over the last 7 days of the Run-in
Increase in Asthma Control Questionnaire 5 (ACQ-5; see Outcome Measure 2 for description) score of ≥ 0.5 compared to baseline
The occurrence of a severe asthma exacerbation (asthma attack) defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.
Secondary Outcome Measures
Change From Baseline to Week 24 in Asthma Control Questionnaire - 5 (ACQ-5) Score
The ACQ-5 is a 5-item questionnaire which has been developed as a measure of the participant's asthma control that can be quickly and easily completed. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms in the prior week (nocturnal awakening, activity limitation, shortness of breath, wheeze). The response options for each of these questions consists of a zero (no impairment/limitation) to 6 (total impairment/limitation) scale.
Change From Baseline to Week 24 in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Pre-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.
Time to First Asthma Worsening
Time to first asthma worsening is defined as the time from the date of the first dose of study treatment to the first date that any of the components of asthma worsening endpoint is met. See Outcome Measure 1 for the definition of asthma worsening.
Annualized Rate of Severe Asthma Exacerbations
A severe asthma exacerbation is defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.
Change From Baseline to Week 24 in Post-Bronchodilator FEV1
Post-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.
Change From Baseline to Week 24 in Morning Peak Expiratory Flow (AM PEF)
AM PEF was measured by participants using an electronic diary.
Percentage of Participants With a Treatment-Emergent Adverse Event (AE)
An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to study treatment. Abnormal laboratory test results or other safety assessments, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator were to be reported as AEs.
Full Information
NCT ID
NCT03683576
First Posted
September 11, 2018
Last Updated
August 20, 2021
Sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03683576
Brief Title
GB001 in Adult Subjects With Moderate to Severe Asthma
Official Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multi-center Study to Evaluate the Efficacy and Safety of GB001 as Maintenance Therapy in Adult Subjects With Moderate to Severe Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
October 22, 2018 (Actual)
Primary Completion Date
July 23, 2020 (Actual)
Study Completion Date
August 18, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
GB001, eosinophilic asthma, moderate asthma, severe asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
481 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo once per day (QD) for 24 weeks
Arm Title
GB001 20 mg
Arm Type
Experimental
Arm Description
GB001 20 mg QD for 24 weeks
Arm Title
GB001 40 mg
Arm Type
Experimental
Arm Description
GB001 40 mg QD for 24 weeks
Arm Title
GB001 60 mg
Arm Type
Experimental
Arm Description
GB001 60 mg QD for 24 weeks
Intervention Type
Drug
Intervention Name(s)
GB001
Intervention Description
film-coated oral tablet
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
film-coated oral tablet
Primary Outcome Measure Information:
Title
Proportion of Participants Who Experience Worsening of Asthma by Week 24
Description
Proportion of participants who experience worsening of asthma by Week 24 as defined by at least 1 of the following:
On 2 consecutive days, morning (AM) peak expiratory flow (PEF) ≤ 75% of mean AM PEF measured over the last 7 days of the Run-in
Forced expiratory volume in 1 second (FEV1) < 80% of baseline
Increase in rescue medication use of ≥ 6 puffs/day on 2 consecutive days compared to mean use over the last 7 days of the Run-in
Increase in Asthma Control Questionnaire 5 (ACQ-5; see Outcome Measure 2 for description) score of ≥ 0.5 compared to baseline
The occurrence of a severe asthma exacerbation (asthma attack) defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.
Time Frame
up to Week 24
Secondary Outcome Measure Information:
Title
Change From Baseline to Week 24 in Asthma Control Questionnaire - 5 (ACQ-5) Score
Description
The ACQ-5 is a 5-item questionnaire which has been developed as a measure of the participant's asthma control that can be quickly and easily completed. The questions are designed to be self-completed by the participant. The 5 questions enquire about the frequency and/or severity of symptoms in the prior week (nocturnal awakening, activity limitation, shortness of breath, wheeze). The response options for each of these questions consists of a zero (no impairment/limitation) to 6 (total impairment/limitation) scale.
Time Frame
Baseline, Week 24
Title
Change From Baseline to Week 24 in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Description
Pre-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.
Time Frame
Baseline, Week 24
Title
Time to First Asthma Worsening
Description
Time to first asthma worsening is defined as the time from the date of the first dose of study treatment to the first date that any of the components of asthma worsening endpoint is met. See Outcome Measure 1 for the definition of asthma worsening.
Time Frame
up to Week 24
Title
Annualized Rate of Severe Asthma Exacerbations
Description
A severe asthma exacerbation is defined as deterioration of asthma that leads to the use of systemic corticosteroids for at least 3 days, hospitalization, or an Emergency Department visit.
Time Frame
up to Week 24
Title
Change From Baseline to Week 24 in Post-Bronchodilator FEV1
Description
Post-albuterol/salbutamol morning FEV1 was measured using electronic spirometry.
Time Frame
Baseline, Week 24
Title
Change From Baseline to Week 24 in Morning Peak Expiratory Flow (AM PEF)
Description
AM PEF was measured by participants using an electronic diary.
Time Frame
Baseline, Week 24
Title
Percentage of Participants With a Treatment-Emergent Adverse Event (AE)
Description
An adverse event (AE) is any untoward medical occurrence in a participant, whether or not considered related to study treatment. Abnormal laboratory test results or other safety assessments, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator were to be reported as AEs.
Time Frame
From first dose of study treatment through Week 28
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
74 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria
A diagnosis of asthma by a physician at least 12 months before Screening Visit.
Treated with medium or high dose inhaled corticosteroid (ICS) plus additional controller for at least 12 months prior to Screening Visit. Subjects must maintain a stable ICS dose regimen during the 4 weeks prior to the Screening Visit.
Forced Expiratory Volume in 1 second (FEV1) of ≤ 85% of predicted normal
Demonstrated reversibility of at least 12% in FEV1
Evidence of uncontrolled asthma
Eosinophilic asthma
No changes in ICS dose and compliant with standard of care asthma therapy during run-in period.
Exclusion Criteria
Current smokers (any substance)
Serious co-morbidities
Fridericia's correction QT factor (QTcF) ≥450 msec (male) or ≥470 msec (female)
Use of other investigational drugs within 30 days, or within 5 half-lives, whichever is longer, prior to Screening Visit
Regular use of systemic corticosteroids or immunosuppressive treatments or monoclonal antibodies for asthma
Pregnant or breastfeeding
Other protocol-defined inclusion/exclusion criteria may apply.
Facility Information:
Facility Name
Clinical Research Center of Albama, LLC
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35209
Country
United States
Facility Name
Banner University of Arizona Medical Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Facility Name
California Allergy and Asthma Medical Group
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Facility Name
Southern California Institute for Respiratory Diseases, Inc.
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
North Bay Clinical Trials, Inc
City
Napa
State/Province
California
ZIP/Postal Code
94558
Country
United States
Facility Name
Allergy, Asthma & Sinus Consultants, Inc
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
Facility Name
Integrated Research of Inland, Inc.
City
Riverside
State/Province
California
ZIP/Postal Code
92506
Country
United States
Facility Name
Allergy & Asthma Medical Group and Research Center, A P.C.
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Allergy and Asthma Associates of Santa Clara Valley Research Center
City
San Jose
State/Province
California
ZIP/Postal Code
95117
Country
United States
Facility Name
Bensch Clinical Research LLC
City
Stockton
State/Province
California
ZIP/Postal Code
95207
Country
United States
Facility Name
Pulmonary Associates
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80909
Country
United States
Facility Name
Yale New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
Central Florida Pulmonary Group, PA
City
Altamonte Springs
State/Province
Florida
ZIP/Postal Code
32701
Country
United States
Facility Name
Central Florida Pulmonary Group, PA
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Emerald Coast Research Associates
City
Panama City
State/Province
Florida
ZIP/Postal Code
32405
Country
United States
Facility Name
Allergy and Asthma Diagnostic Treatment Center
City
Tallahassee
State/Province
Florida
ZIP/Postal Code
32308
Country
United States
Facility Name
Clinical Research Trials of Florida, Inc.
City
Tampa
State/Province
Florida
ZIP/Postal Code
33607
Country
United States
Facility Name
The Emory Clinic
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Atlanta Allergy & Asthma Clinic, PA,
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Atlanta Allergy & Asthma Clinic, PA
City
Stockbridge
State/Province
Georgia
ZIP/Postal Code
30281
Country
United States
Facility Name
Treasure Valley Medical Research
City
Boise
State/Province
Idaho
ZIP/Postal Code
83706
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Allergy & Asthma Specialists, PSC
City
Owensboro
State/Province
Kentucky
ZIP/Postal Code
42301
Country
United States
Facility Name
John Hopkins Asthma and Allergy Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
University of Michigan Medicine
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Clinical Research Institute, Inc.
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55402
Country
United States
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63108
Country
United States
Facility Name
Atlantic Research Center, LLC
City
Ocean City
State/Province
New Jersey
ZIP/Postal Code
07712
Country
United States
Facility Name
American Health Research
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28207
Country
United States
Facility Name
Clinical Research of Charlotte
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28277
Country
United States
Facility Name
Wake Forest Baptist Health
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27104
Country
United States
Facility Name
Bernstein Clinical Research Center, LLC
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45231
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Oklahoma Institute of Allergy & Asthma Clinical Research, LLC
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73131
Country
United States
Facility Name
Crisor, LLC
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
Allergy and Clinical Immunology Associates
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15241
Country
United States
Facility Name
Berks Schuylkill Respiratory Specialists, Ltd.
City
Wyomissing
State/Province
Pennsylvania
ZIP/Postal Code
19610
Country
United States
Facility Name
AAPRI Clinical Research Institute
City
Warwick
State/Province
Rhode Island
ZIP/Postal Code
02886
Country
United States
Facility Name
Clinical Research of Rock Hill
City
Rock Hill
State/Province
South Carolina
ZIP/Postal Code
29732
Country
United States
Facility Name
Corsicana Medical Research, LLC
City
Corsicana
State/Province
Texas
ZIP/Postal Code
75110
Country
United States
Facility Name
Western Sky Medical Research
City
El Paso
State/Province
Texas
ZIP/Postal Code
79903
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Allergy and Asthma Research Center, PA
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Pulmonary Research of Abingdon, LLC
City
Abingdon
State/Province
Virginia
ZIP/Postal Code
24210
Country
United States
Facility Name
MultiCare Institute for Research & Innovation
City
Tacoma
State/Province
Washington
ZIP/Postal Code
98405
Country
United States
Facility Name
University of Wisconsin School of Medicine and Public Health Asthma, Allergy, and Pulmonary Clinical Research
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792-9988
Country
United States
Facility Name
Ordination Dr. Robert Voves
City
Feldbach
ZIP/Postal Code
8330
Country
Austria
Facility Name
SALK University Hospital Salzburg, State Hospital Salzburg
City
Salzburg
Country
Austria
Facility Name
Medical University of Vienna, Department of Internal Medicine II, Clinical Division of Pulmonolog
City
Vienna
Country
Austria
Facility Name
UCL Saint-Luc - Pneumology Department
City
Bruxelles
Country
Belgium
Facility Name
Pneumocare sprl
City
Erpent
Country
Belgium
Facility Name
UZ Gent - Department of Respiratory Medicine
City
Gent
Country
Belgium
Facility Name
CHU de Charleroi - Site André Vésale
City
Montigny-le-Tilleul
Country
Belgium
Facility Name
Inspiration Research Limited
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 3A9
Country
Canada
Facility Name
CHUM - Departement de pneumologie
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2X 3E4
Country
Canada
Facility Name
Allergiste & Immunologue - Clinic/Outpatient Facility
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3G 1L5
Country
Canada
Facility Name
Centre integre universitaire de sante et de services sociaux du Nord-de-I'lle-de-Montreal - Hopital du Sacre-Coeur de Montreal
City
Montréal
Country
Canada
Facility Name
Dr. Jamie Del Carpio's Clinic
City
Montréal
Country
Canada
Facility Name
Inspirational Research Limited
City
Toronto
Country
Canada
Facility Name
C. I. C Mauricie Inc.
City
Trois-Rivières
Country
Canada
Facility Name
The Lung Centre, Vancouver General Hospital
City
Vancouver
Country
Canada
Facility Name
St. Anne's University Hospital Brno, Institute of Clinical Immunology and Allergology
City
Brno
Country
Czechia
Facility Name
University Hospital Hradec Kralove, Institute of Clinical Immunology and Allergollogy
City
Hradec Kralove
Country
Czechia
Facility Name
MediTrial s.r.o.
City
Jindrichuv Hradec
ZIP/Postal Code
37701
Country
Czechia
Facility Name
PNEUMO-KV s.r.o.
City
Karlovy Vary
ZIP/Postal Code
36017
Country
Czechia
Facility Name
Pulmonary Outpatient Clinic - Dr. Otakar Hokynar
City
Kralupy nad Vltavou
ZIP/Postal Code
27801
Country
Czechia
Facility Name
University Hospital Olomouc, Department of Allergology and Clinical Immunology
City
Olomouc
ZIP/Postal Code
779 00
Country
Czechia
Facility Name
Medicon a.s.
City
Praha 4
Country
Czechia
Facility Name
Pulmonary Outpatient Clinic Rokycany s.r.o.
City
Rokycany
ZIP/Postal Code
33722
Country
Czechia
Facility Name
Outpatient Allergology and Neurology Clinic Kasmed Ltd.
City
Tábor
ZIP/Postal Code
39002
Country
Czechia
Facility Name
La Croix Rousse Hospital
City
Lyon
Country
France
Facility Name
Nord G&R Laennec Hospital
City
Nantes
Country
France
Facility Name
Centre Hospitalier Annecy Genevois
City
Pringy
Country
France
Facility Name
NOUVEL HOPITAL CIVIL - New Civil Hospital
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Universitatsklinikum des Saarlandes, Klinik fur Innere Medizin V
City
Homburg
State/Province
Saarland
ZIP/Postal Code
66421
Country
Germany
Facility Name
RCMS Dr. Linhoff
City
Berlin
ZIP/Postal Code
10717
Country
Germany
Facility Name
Pneumologisches Studienzentrum Margrafenstrasse
City
Berlin
ZIP/Postal Code
10969
Country
Germany
Facility Name
Institut fuer Allergie - und Asthmaforschung
City
Berlin
ZIP/Postal Code
12159
Country
Germany
Facility Name
Pneumologische Praxis am Schloss
City
Berlin
Country
Germany
Facility Name
IKF Pneumologie GmbH & Co. KG
City
Frankfurt am Main
ZIP/Postal Code
60596
Country
Germany
Facility Name
Pneumologicum im Suedstadtforum
City
Hannover
ZIP/Postal Code
30173
Country
Germany
Facility Name
Schmid
City
Koblenz
ZIP/Postal Code
56068
Country
Germany
Facility Name
BAG Prof. Hoheisel/Dr. A. Bonitz
City
Leipzig
ZIP/Postal Code
04275
Country
Germany
Facility Name
Pneumologische Praxis PD Dr. med.
City
Leipzig
Country
Germany
Facility Name
KLB Gesundheitsforschung Luebeck GmbH
City
Luebeck
ZIP/Postal Code
23552
Country
Germany
Facility Name
Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Hospital
City
Mainz
Country
Germany
Facility Name
Centrum Medycyny Oddechowej Mroz sp. j.
City
Białystok
Country
Poland
Facility Name
Malopolskie Centrum Alergologii
City
Kraków
Country
Poland
Facility Name
Niepubliczny Zaklad Opieki Zdrowotnej (NZOZ)
City
Kraków
Country
Poland
Facility Name
Ostrowieckie Centrum Medyczne
City
Ostrowiec Świętokrzyski
Country
Poland
Facility Name
SPZOZ Proszowice
City
Proszowice
Country
Poland
Facility Name
Gabinet Lekarski Zenon Bukowczan
City
Sucha Beskidzka
Country
Poland
Facility Name
ALL-MED - Specjalistyczna Opieka Medyczna - Medyczny Instytut Badawczy Marek Jutel
City
Wrocław
Country
Poland
Facility Name
Centrum Medyczne Melita Medical
City
Wrocław
Country
Poland
Facility Name
NZOZ Lekarze Specjalisci
City
Wrocław
Country
Poland
Facility Name
SPZOZ Uniwersytecki Szpital Kliniczny nr 1
City
Łódź
Country
Poland
Facility Name
Hospital Clinico Universitario de Santiago de Compostela
City
Santiago De Compostela
State/Province
A Coruna
ZIP/Postal Code
15706
Country
Spain
Facility Name
Hospital Universitario de Bellvitge
City
L'Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Instituto de Ciencias Medicas
City
Alicante
ZIP/Postal Code
03004
Country
Spain
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
Country
Spain
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
Country
Spain
Facility Name
Hospital Universitario Doctor Peset
City
Valencia
ZIP/Postal Code
46017
Country
Spain
Facility Name
Public Institution: Dnipro Clinical Association of Urgent Medical Care under Dnipro City Council
City
Dnipro
ZIP/Postal Code
49006
Country
Ukraine
Facility Name
Public Institution "City Clinical Hospital #4" under Dnipro City Council
City
Dnipro
ZIP/Postal Code
49102
Country
Ukraine
Facility Name
Ivano-Frankivsk Central City Clinical Hospital
City
Ivano-Frankivsk
ZIP/Postal Code
76018
Country
Ukraine
Facility Name
Public Non-Profit Enterprise: City Clinical Hospital #13 under Kharkiv City Council
City
Kharkiv
Country
Ukraine
Facility Name
State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"
City
Kyiv
ZIP/Postal Code
03680
Country
Ukraine
Facility Name
State Organization "National Institute of Phthisiology and Pulmonolgy named after F.G. Yanovsky NAMSU"
City
Kyiv
Country
Ukraine
Facility Name
Public Institution: City Clinical Hospital #6
City
Zaporizhia
ZIP/Postal Code
69035
Country
Ukraine
Facility Name
Public Non-Profit Enterprise City Hospital #1 under Zaporizhia City Council
City
Zaporizhia
ZIP/Postal Code
69104
Country
Ukraine
Facility Name
Public Enterprise "Hospital #1" under Zhytomyr City Council
City
Zhytomyr
ZIP/Postal Code
10002
Country
Ukraine
Facility Name
Birmingham Heartlands Hospital
City
Birmingham
Country
United Kingdom
Facility Name
Bradford Royal Infirmary
City
Bradford
Country
United Kingdom
Facility Name
Glasgow Clinical Research Facility, Glasgow Royal Infirmary
City
Glasgow
Country
United Kingdom
Facility Name
Royal Liverpool University Hospital
City
Liverpool
Country
United Kingdom
Facility Name
University Hospital Southampton
City
Southampton
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
35248549
Citation
Moss MH, Lugogo NL, Castro M, Hanania NA, Ludwig-Sengpiel A, Saralaya D, Dobek R, Ojanguren I, Vyshnyvetskyy I, Bruey JM, Osterhout R, Tompkins CA, Dittrich K, Raghupathi K, Ortega H; LEDA Investigators. Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma. Chest. 2022 Aug;162(2):297-308. doi: 10.1016/j.chest.2022.02.038. Epub 2022 Mar 3.
Results Reference
derived
PubMed Identifier
31659803
Citation
Ortega H, Fitzgerald M, Raghupathi K, Tompkins CA, Shen J, Dittrich K, Pattwell C, Singh D. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma. Clin Exp Allergy. 2020 Feb;50(2):189-197. doi: 10.1111/cea.13524. Epub 2019 Nov 26.
Results Reference
derived
Learn more about this trial
GB001 in Adult Subjects With Moderate to Severe Asthma
We'll reach out to this number within 24 hrs